Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
combination therapy
Biotech
Ipsen inks €1B buyout of French biotech ImCheck
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck for its investigational cancer combo therapy in a deal worth up $1.16 billion.
Gabrielle Masson
Oct 22, 2025 10:33am
Fierce Pharma
Big Pharma bets big on MASH with a new combo playbook
Oct 17, 2025 9:30am
BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC
Sep 8, 2025 11:00am
Immutep's LAG-3 agent posts 'impressive' survival data
May 5, 2025 10:37am
Amgen and Ideaya ax cancer combination trial
Feb 13, 2025 7:34am
Lilly's oral SERD Ember counts on Verzenio to broaden its glow
Dec 11, 2024 8:15am
